- Vaccinex Reports 2023 Financial Results and Provides Corporate Update
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
- Vaccinex, Inc. Announces Reverse Stock Split
- Vaccinex Announces Pricing of $3.7 Million PIPE Financing
- Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
- Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
- Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
- Vaccinex Announces Pricing of $9.6 Million Public Offering
More ▼
Key statistics
On Friday, Vaccinex Inc (VCNX:NAQ) closed at 6.05, 36.51% above the 52 week low of 4.43 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.43 |
---|---|
High | 6.59 |
Low | 6.01 |
Bid | 5.10 |
Offer | 6.61 |
Previous close | 6.18 |
Average volume | 6.93k |
---|---|
Shares outstanding | 1.58m |
Free float | 1.47m |
P/E (TTM) | -- |
Market cap | 9.59m USD |
EPS (TTM) | -63.98 USD |
Data delayed at least 15 minutes, as of May 03 2024 20:59 BST.
More ▼